Compare NRT & MXCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NRT | MXCT |
|---|---|---|
| Founded | 1975 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 76.7M | 93.0M |
| IPO Year | 1995 | 2021 |
| Metric | NRT | MXCT |
|---|---|---|
| Price | $7.99 | $0.82 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.50 |
| AVG Volume (30 Days) | 79.5K | ★ 770.8K |
| Earning Date | 05-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 9.65% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.21 | N/A |
| Revenue | N/A | ★ $33,026,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $18.50 |
| P/E Ratio | $39.81 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.36 | $0.64 |
| 52 Week High | $10.49 | $2.88 |
| Indicator | NRT | MXCT |
|---|---|---|
| Relative Strength Index (RSI) | 41.50 | 50.04 |
| Support Level | $7.51 | $0.75 |
| Resistance Level | $9.52 | $0.88 |
| Average True Range (ATR) | 0.41 | 0.05 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 25.80 | 50.63 |
North European Oil Royalty Trust holds overriding royalty rights covering gas and oil production in certain concessions or leases in the Federal Republic of Germany. The properties of the trust are overriding royalty rights on sales of gas, sulfur, and oil under certain concessions or leases in the Federal Republic of Germany. The trust also holds other royalty rights, which are based on leases. It receives various percentages of royalties on the proceeds of the sales of certain products from the areas involved.
MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.